hypoxia

YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial

...to increase the risk of key adverseevents (such as hypoxia and bradypnea) and has the potential tominimize certain otherwise expected adverse effects of interest topatients and physicians, warranting further investigation anddevelopment. "These results, from this difficult to treat patient population,confir...

Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer

... more often in the EFAPROXYN armincluded headache, hypoxia and vomiting. Adverse events in thestudy appeared to be similar to those observed in previous clinicalstudies with EFAPROXYN. "Although we are disappointed with the results of the ENRICHstudy, we are excited about the potential of our product pipeli...

Clinical Results From EntreMed's Panzem NCD and Taxol Breast Cancer Study Presented at ASCO

... biopsies of their tumors toevaluate biomarkers of hypoxia and angiogenesis. Paclitaxel causesan increase in tumor HIF-1alpha expression, which is downregulatedby 2ME2. Changes were observed in HIF-1 regulated proteins,including tissue VEGF, VEGFR-2, plasma PAI-1, and osteopontin.Based on these findings, enr...

Phase 2 Results for EntreMed's Panzem NCD Brain Cancer Study Presented at ASCO

...isruption ofangiogenesis through the inhibition of hypoxia inducible factor-1alpha (HIF-1alpha), a protein required for angiogenesis and cellsurvival under stress. By these mechanisms, Panzem(R) has thepotential to attack cancer cells through multiple pathways thataffect the formation and replication of tumo...

The Eloxatin-Based Regimen (FOLFOX4) Significantly Improved Progression Free Survival When Given Before and After Surgery in Patients With Resectable Liver Metastases From Colorectal Cancer

...arm. The combined incidence of cough, dyspnea, and hypoxia was 43% (7% grade 3 and 4) in the Eloxatin(R) plus 5-FU/LV arm compared to 32% (5% grade 3 and 4) in the irinotecan plus 5-FU/LV arm in patients with previously untreated colorectal cancer. In case of unexplained respiratory sympt...

Kosan Presents Promising Phase 1 Data on Second-Generation Hsp90 Inhibitor, Alvespimycin, Showing Antitumor Activity in Refractory Breast and Ovarian Cancers at ASCO

...ng regimens experienced adose-limiting toxicity of hypoxia and left ventricular ejectionfraction reduction at 100 mg/m2. Two patients treated at 80 mg/m2experienced reversible Grade 3 ocular keratitis; following atreatment holiday both patients continued therapy with reduceddoses (one patient remains on stud...

Data to be Presented at ASCO 2007 Highlights sanofi-aventis Commitment to Cancer Care and Research

...arm. The combined incidence of cough, dyspnea, and hypoxia was 43% (7% grade 3 and 4) in the Eloxatin(R) plus 5-FU/LV arm compared to 32% (5% grade 3 and 4) in the irinotecan plus 5-FU/LV arm in patients with previously untreated colorectal cancer. In case of unexplained respiratory s...